Revvity Inc Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)1.05 Intrinsic Value $74.88median of 6 methods · middle span $42-$112based on filings through 5 Jul 2026 Market Price $149.06Price as of 1 Oct 2026 OvervaluedIntrinsic value is 50% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $16.6B Enterprise Value $18.8B Shares Outstanding 109.5M diluted Moat Rating None Next Earnings Date26 Oct 2026 Next ex-dividend23 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Revvity entered the second half of 2026 with improving consolidated demand, raised full-year guidance and strong Diagnostics growth, but the recovery remained uneven: second-quarter pro forma organic growth was 3%, Diagnostics grew 11%, and Life Sciences declined 3%. The balanced stance reflects credible operating momentum and new Signals AI capabilities offset by continued Life Sciences weakness, reliance on non-GAAP guidance and execution risk surrounding the planned China Immunodiagnostics divestiture. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$100.00 Mean target$121.07 High · most bullish analyst$145.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $100.0024% Life Sciences weakness persists, consolidated organic growth falls below the 4% guidance floor, or adjusted EPS falls below $5.30. Additional downside would arise from disruption or delay in the China Immunodiagnostics divestiture, which concerns a business representing approximately 6% of 2025 revenue. Base CaseCentral scenario $121.0757% Matches the consensus meanRevvity broadly achieves its 2026 guidance while performance remains mixed between strong Diagnostics and softer Life Sciences. Margin and earnings progress continue, but part of second-quarter adjusted EPS benefited from tariff refunds, warranting a neutral stance until underlying Life Sciences demand improves. Bull CaseUpside scenario $145.0019% Demand improvement broadens beyond Diagnostics, Life Sciences returns to growth, and Revvity delivers near the upper ends of its 4%-5% organic-growth and $5.30-$5.40 adjusted-EPS guidance. Signals AI and its Claude integration strengthen adoption of the Signals platform. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |